Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis

Abstract Atherosclerosis is a progressive disease in which endothelial cell dysfunction, macrophage foam cell formation, and smooth muscle cell migration and proliferation, lead to the loss of vascular homeostasis. Oxidized low-density lipoprotein (OxLDL) may play a pre-eminent function in atheroscl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vascular pharmacology 2016-09, Vol.84, p.1-7
Hauptverfasser: Di Pietro, Natalia, Formoso, Gloria, Pandolfi, Assunta
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7
container_issue
container_start_page 1
container_title Vascular pharmacology
container_volume 84
creator Di Pietro, Natalia
Formoso, Gloria
Pandolfi, Assunta
description Abstract Atherosclerosis is a progressive disease in which endothelial cell dysfunction, macrophage foam cell formation, and smooth muscle cell migration and proliferation, lead to the loss of vascular homeostasis. Oxidized low-density lipoprotein (OxLDL) may play a pre-eminent function in atherosclerotic lesion formation, even if their role is still debated. Several types of scavenger receptors (SRs) such as SR-AI/II, SRBI, CD36, lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), toll-like receptors (TLRs) and others can promote the internalization of oxLDL. They are expressed on the surface of vascular wall cells (endothelial cells, macrophages and smooth muscle cells) and they mediate the cellular effects of OxLDL. The key influence of both OxLDL and SRs on the atherogenic process has been established in atherosclerosis-prone animals, in which antioxidant treatment and/or silencing of SRs has been shown to reduce atherogenesis. Despite some discrepancies, the indication from cohort studies that there is an association between oxLDL and cardiovascular (CV) events seems to point towards a role for oxLDL in atherosclerotic plaque progress and disruption. Finally, randomized clinical trials using antioxidants have demonstrated benefits only in high-risk patients, suggesting that additional proofs are still needed to better define the involvement of each type of modified LDL in the development of atherosclerosis.
doi_str_mv 10.1016/j.vph.2016.05.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1810066758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1537189115301014</els_id><sourcerecordid>1810066758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-42f639c9f5a67f1e6f8a3a8e48943bb5f9e83231dcac37b243d0ab14ff6522963</originalsourceid><addsrcrecordid>eNp9kU2r1DAUhoso3uvVH-BGsnTTmq-mCYIg108YUFDBXUjTEydzM01N2tH-e1PmquDCTc4hvO_LOc-pqscENwQT8ezQnKZ9Q0vb4LbBhN2pLonsVM0EV3dL37KuJlKRi-pBzgeMiZRC3a8uaEdboai8rL5-3K_ZxxC_rciMA5rMvI_T37_oUPy5e7VDyzSbG0D9ik4m2yWYhH6YEJCFEDLyIypGSDHbsL0-P6zuORMyPLqtV9WXN68_X7-rdx_evr9-uast7_hcc-oEU1a51ojOERBOGmYkcKk46_vWKZCMMjJYY1nXU84GbHrCnRMtpUqwq-rpOXdK8fsCedZHn7ehzAhxyZpIgrEQXSuLlJyltkyYEzg9JX80adUE6w2oPugCVG9ANW51AVo8T27jl_4Iwx_Hb4JF8PwsgLLkyUPS2XoYLQw-gZ31EP1_41_847bBj96acAMr5ENc0ljoaaIz1Vh_2i66HbRUXCI5-wUUgpwW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1810066758</pqid></control><display><type>article</type><title>Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Di Pietro, Natalia ; Formoso, Gloria ; Pandolfi, Assunta</creator><creatorcontrib>Di Pietro, Natalia ; Formoso, Gloria ; Pandolfi, Assunta</creatorcontrib><description>Abstract Atherosclerosis is a progressive disease in which endothelial cell dysfunction, macrophage foam cell formation, and smooth muscle cell migration and proliferation, lead to the loss of vascular homeostasis. Oxidized low-density lipoprotein (OxLDL) may play a pre-eminent function in atherosclerotic lesion formation, even if their role is still debated. Several types of scavenger receptors (SRs) such as SR-AI/II, SRBI, CD36, lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), toll-like receptors (TLRs) and others can promote the internalization of oxLDL. They are expressed on the surface of vascular wall cells (endothelial cells, macrophages and smooth muscle cells) and they mediate the cellular effects of OxLDL. The key influence of both OxLDL and SRs on the atherogenic process has been established in atherosclerosis-prone animals, in which antioxidant treatment and/or silencing of SRs has been shown to reduce atherogenesis. Despite some discrepancies, the indication from cohort studies that there is an association between oxLDL and cardiovascular (CV) events seems to point towards a role for oxLDL in atherosclerotic plaque progress and disruption. Finally, randomized clinical trials using antioxidants have demonstrated benefits only in high-risk patients, suggesting that additional proofs are still needed to better define the involvement of each type of modified LDL in the development of atherosclerosis.</description><identifier>ISSN: 1537-1891</identifier><identifier>EISSN: 1879-3649</identifier><identifier>DOI: 10.1016/j.vph.2016.05.013</identifier><identifier>PMID: 27256928</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Atherosclerosis ; Atherosclerosis - physiopathology ; Cardiovascular ; Disease Progression ; Endothelial Cells - metabolism ; Foam Cells - metabolism ; Humans ; Lipoproteins, LDL - metabolism ; Macrophages ; Macrophages - metabolism ; Myocytes, Smooth Muscle - metabolism ; Oxidized low-density lipoproteins ; Plaque, Atherosclerotic - pathology ; Randomized Controlled Trials as Topic</subject><ispartof>Vascular pharmacology, 2016-09, Vol.84, p.1-7</ispartof><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-42f639c9f5a67f1e6f8a3a8e48943bb5f9e83231dcac37b243d0ab14ff6522963</citedby><cites>FETCH-LOGICAL-c474t-42f639c9f5a67f1e6f8a3a8e48943bb5f9e83231dcac37b243d0ab14ff6522963</cites><orcidid>0000-0001-8692-8827</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.vph.2016.05.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27256928$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Pietro, Natalia</creatorcontrib><creatorcontrib>Formoso, Gloria</creatorcontrib><creatorcontrib>Pandolfi, Assunta</creatorcontrib><title>Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis</title><title>Vascular pharmacology</title><addtitle>Vascul Pharmacol</addtitle><description>Abstract Atherosclerosis is a progressive disease in which endothelial cell dysfunction, macrophage foam cell formation, and smooth muscle cell migration and proliferation, lead to the loss of vascular homeostasis. Oxidized low-density lipoprotein (OxLDL) may play a pre-eminent function in atherosclerotic lesion formation, even if their role is still debated. Several types of scavenger receptors (SRs) such as SR-AI/II, SRBI, CD36, lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), toll-like receptors (TLRs) and others can promote the internalization of oxLDL. They are expressed on the surface of vascular wall cells (endothelial cells, macrophages and smooth muscle cells) and they mediate the cellular effects of OxLDL. The key influence of both OxLDL and SRs on the atherogenic process has been established in atherosclerosis-prone animals, in which antioxidant treatment and/or silencing of SRs has been shown to reduce atherogenesis. Despite some discrepancies, the indication from cohort studies that there is an association between oxLDL and cardiovascular (CV) events seems to point towards a role for oxLDL in atherosclerotic plaque progress and disruption. Finally, randomized clinical trials using antioxidants have demonstrated benefits only in high-risk patients, suggesting that additional proofs are still needed to better define the involvement of each type of modified LDL in the development of atherosclerosis.</description><subject>Animals</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis - physiopathology</subject><subject>Cardiovascular</subject><subject>Disease Progression</subject><subject>Endothelial Cells - metabolism</subject><subject>Foam Cells - metabolism</subject><subject>Humans</subject><subject>Lipoproteins, LDL - metabolism</subject><subject>Macrophages</subject><subject>Macrophages - metabolism</subject><subject>Myocytes, Smooth Muscle - metabolism</subject><subject>Oxidized low-density lipoproteins</subject><subject>Plaque, Atherosclerotic - pathology</subject><subject>Randomized Controlled Trials as Topic</subject><issn>1537-1891</issn><issn>1879-3649</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2r1DAUhoso3uvVH-BGsnTTmq-mCYIg108YUFDBXUjTEydzM01N2tH-e1PmquDCTc4hvO_LOc-pqscENwQT8ezQnKZ9Q0vb4LbBhN2pLonsVM0EV3dL37KuJlKRi-pBzgeMiZRC3a8uaEdboai8rL5-3K_ZxxC_rciMA5rMvI_T37_oUPy5e7VDyzSbG0D9ik4m2yWYhH6YEJCFEDLyIypGSDHbsL0-P6zuORMyPLqtV9WXN68_X7-rdx_evr9-uast7_hcc-oEU1a51ojOERBOGmYkcKk46_vWKZCMMjJYY1nXU84GbHrCnRMtpUqwq-rpOXdK8fsCedZHn7ehzAhxyZpIgrEQXSuLlJyltkyYEzg9JX80adUE6w2oPugCVG9ANW51AVo8T27jl_4Iwx_Hb4JF8PwsgLLkyUPS2XoYLQw-gZ31EP1_41_847bBj96acAMr5ENc0ljoaaIz1Vh_2i66HbRUXCI5-wUUgpwW</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Di Pietro, Natalia</creator><creator>Formoso, Gloria</creator><creator>Pandolfi, Assunta</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8692-8827</orcidid></search><sort><creationdate>20160901</creationdate><title>Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis</title><author>Di Pietro, Natalia ; Formoso, Gloria ; Pandolfi, Assunta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-42f639c9f5a67f1e6f8a3a8e48943bb5f9e83231dcac37b243d0ab14ff6522963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis - physiopathology</topic><topic>Cardiovascular</topic><topic>Disease Progression</topic><topic>Endothelial Cells - metabolism</topic><topic>Foam Cells - metabolism</topic><topic>Humans</topic><topic>Lipoproteins, LDL - metabolism</topic><topic>Macrophages</topic><topic>Macrophages - metabolism</topic><topic>Myocytes, Smooth Muscle - metabolism</topic><topic>Oxidized low-density lipoproteins</topic><topic>Plaque, Atherosclerotic - pathology</topic><topic>Randomized Controlled Trials as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Pietro, Natalia</creatorcontrib><creatorcontrib>Formoso, Gloria</creatorcontrib><creatorcontrib>Pandolfi, Assunta</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Vascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Pietro, Natalia</au><au>Formoso, Gloria</au><au>Pandolfi, Assunta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis</atitle><jtitle>Vascular pharmacology</jtitle><addtitle>Vascul Pharmacol</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>84</volume><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>1537-1891</issn><eissn>1879-3649</eissn><abstract>Abstract Atherosclerosis is a progressive disease in which endothelial cell dysfunction, macrophage foam cell formation, and smooth muscle cell migration and proliferation, lead to the loss of vascular homeostasis. Oxidized low-density lipoprotein (OxLDL) may play a pre-eminent function in atherosclerotic lesion formation, even if their role is still debated. Several types of scavenger receptors (SRs) such as SR-AI/II, SRBI, CD36, lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), toll-like receptors (TLRs) and others can promote the internalization of oxLDL. They are expressed on the surface of vascular wall cells (endothelial cells, macrophages and smooth muscle cells) and they mediate the cellular effects of OxLDL. The key influence of both OxLDL and SRs on the atherogenic process has been established in atherosclerosis-prone animals, in which antioxidant treatment and/or silencing of SRs has been shown to reduce atherogenesis. Despite some discrepancies, the indication from cohort studies that there is an association between oxLDL and cardiovascular (CV) events seems to point towards a role for oxLDL in atherosclerotic plaque progress and disruption. Finally, randomized clinical trials using antioxidants have demonstrated benefits only in high-risk patients, suggesting that additional proofs are still needed to better define the involvement of each type of modified LDL in the development of atherosclerosis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27256928</pmid><doi>10.1016/j.vph.2016.05.013</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-8692-8827</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1537-1891
ispartof Vascular pharmacology, 2016-09, Vol.84, p.1-7
issn 1537-1891
1879-3649
language eng
recordid cdi_proquest_miscellaneous_1810066758
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Atherosclerosis
Atherosclerosis - physiopathology
Cardiovascular
Disease Progression
Endothelial Cells - metabolism
Foam Cells - metabolism
Humans
Lipoproteins, LDL - metabolism
Macrophages
Macrophages - metabolism
Myocytes, Smooth Muscle - metabolism
Oxidized low-density lipoproteins
Plaque, Atherosclerotic - pathology
Randomized Controlled Trials as Topic
title Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T04%3A06%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Physiology%20and%20pathophysiology%20of%20oxLDL%20uptake%20by%20vascular%20wall%20cells%20in%20atherosclerosis&rft.jtitle=Vascular%20pharmacology&rft.au=Di%20Pietro,%20Natalia&rft.date=2016-09-01&rft.volume=84&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=1537-1891&rft.eissn=1879-3649&rft_id=info:doi/10.1016/j.vph.2016.05.013&rft_dat=%3Cproquest_cross%3E1810066758%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1810066758&rft_id=info:pmid/27256928&rft_els_id=1_s2_0_S1537189115301014&rfr_iscdi=true